Form 4: Brainstorm Cell Therapeutics CEO Acquires 15,000 Shares

Chaim Lebovits, President and CEO of Brainstorm Cell Therapeutics, recently acquired 15,000 shares of common stock at a price of $0.5199 per share.

Summary

• On April 19, 2024, Chaim Lebovits, the President and CEO of Brainstorm Cell Therapeutics Inc., acquired 15,000 shares of the company's common stock.
• The shares were purchased at a price of $0.5199 per share.
• Following the transaction, Lebovits directly owns 858,565 shares of common stock.
• Lebovits may also be deemed the beneficial owner of 2,000,847 indirectly held shares.
• These indirectly held shares include 1,933,794 shares owned by ACCBT Corp. and 67,053 shares owned by ACC International Holdings Ltd.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO's purchase is a positive sign, but it's a relatively small transaction and doesn't provide definitive insight into the company's overall prospects.

Positives

• The CEO's purchase of shares could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Insider transactions are closely monitored as they can provide insights into management's perspective on the company's value and future performance. This purchase could be seen as a positive signal, but should be considered alongside other factors.

Stakeholder Impact

• The CEO's stock purchase could have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Brainstorm Cell Therapeutics, BCLI, Chaim Lebovits, Stock Acquisition, SEC Form 4, Insider Trading, Common Stock